Table 1 Clinical characteristics of the pre-TG18 group and post-TG18 group
Variable | Pre-TG18 group (2013–2017, n = 17) | Post-TG18 group (2018–2020, n = 27) | P-value |
|---|---|---|---|
Age (years), median [IQR] | 75 [63–84] | 78 [68–87] | 0.682 |
Sex Male | 6 (35.3%) | 18 (66.7%) | 0.042* |
Severity grade of AC | 0.234 | ||
II | 16 (94.1%) | 22 (81.5%) | |
III | 1 (5.9%) | 5 (18.5%) | |
ASA-PS | 0.143 | ||
I–II | 12 (70.6%) | 13 (48.1%) | |
III or higher | 5 (29.4%) | 14 (51.9%) | |
SIRS | 10 (58.8%) | 18 (66.7%) | 0.599 |
WBC count on admission × 103/μL, median [IQR] | 13.1 [10.7–20.6] | 14.9 [11.9–19.7] | 0.736 |
CCI on admission | 1 [0–2.5] | 2 [1–3] | 0.219 |
Comorbidity | |||
MI | 5 (29.4%) | 6 (22.2%) | 0.592 |
CHF | 1 (5.9%) | 4 (14.8%) | 0.363 |
Peripheral vascular disease | 0 | 3 (11.1) | 0.155 |
Cerebrovascular disease | 3 (17.6%) | 5 (18.5%) | 0.942 |
Dementia | 3 (17.6%) | 6 (22.2%) | 0.714 |
RA | 0 | 2 (7.4%) | 0.251 |
Diabetes | 5 (29.4%) | 8 (29.6%) | 0.988 |
Hemiplegia | 0 | 4 (14.8%) | 0.096 |
CKD | 0 | 2 (7.4%) | 0.251 |
Solid tumor | 1 (5.9%) | 2 (7.4%) | 0.845 |
Lymphoma | 1 (5.9%) | 0 | 0.202 |
Time from onset to PTGBD, days, median [IQR] | 3 [1–7] | 2 [1–3] | 0.126 |
Time from PTGBD to cholecystectomy, days, median [IQR] | 8 [4–11] | 15 [9–42] | 0.010* |